FTC Secures Major Antitrust Settlement with CVS's Caremark
CVS sits 81% above its 52-week low of $58.5.
Summary
The FTC announced a major settlement with CVS's pharmacy benefit manager Caremark, resolving an antitrust case. The settlement mandates lower patient out-of-pocket costs, increased transparency, and fair treatment of community pharmacies. CVS Caremark announced an agreement with the FTC to further advance industry-leading approaches to transparency and affordability. This removes a significant legal overhang for CVS, though specific financial terms or penalties are not disclosed. The resolution follows a recent Florida AG subpoena into Caremark's practices, suggesting broader regulatory scrutiny is being addressed. With CVS trading near its 52-week high, the settlement could reinforce positive sentiment around the company's regulatory risk management.
At the time of this announcement, CVS was trading at $105.62 on NYSE in the Trade & Services sector, with a market capitalization of approximately $134.8B. The 52-week trading range was $58.50 to $106.93. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.